vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Wheels Up Experience Inc. (UP). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $183.8M, roughly 1.5× Wheels Up Experience Inc.). Wheels Up Experience Inc. runs the higher net margin — -15.7% vs -45.7%, a 30.0% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -10.2%). Guardant Health, Inc. produced more free cash flow last quarter ($-54.2M vs $-58.3M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -3.4%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Wheels Up is a provider of "on demand" private aviation in the United States and one of the largest private aviation companies in the world. It was founded in 2013 by Kenny Dichter, using a membership/on-demand business model. Wheels Up members can book private aircraft from the company fleet and third-party operators using a mobile application.
GH vs UP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $183.8M |
| Net Profit | $-128.5M | $-28.9M |
| Gross Margin | 64.6% | 14.3% |
| Operating Margin | -43.0% | -0.9% |
| Net Margin | -45.7% | -15.7% |
| Revenue YoY | 39.4% | -10.2% |
| Net Profit YoY | -15.8% | 67.0% |
| EPS (diluted) | $-1.01 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $183.8M | ||
| Q3 25 | $265.2M | $185.5M | ||
| Q2 25 | $232.1M | $189.6M | ||
| Q1 25 | $203.5M | $177.5M | ||
| Q4 24 | $201.8M | $204.8M | ||
| Q3 24 | $191.5M | $193.9M | ||
| Q2 24 | $177.2M | $196.3M | ||
| Q1 24 | $168.5M | $197.1M |
| Q4 25 | $-128.5M | $-28.9M | ||
| Q3 25 | $-92.7M | $-83.7M | ||
| Q2 25 | $-99.9M | $-82.3M | ||
| Q1 25 | $-95.2M | $-99.3M | ||
| Q4 24 | $-111.0M | $-87.5M | ||
| Q3 24 | $-107.8M | $-57.7M | ||
| Q2 24 | $-102.6M | $-97.0M | ||
| Q1 24 | $-115.0M | $-97.4M |
| Q4 25 | 64.6% | 14.3% | ||
| Q3 25 | 64.7% | 6.8% | ||
| Q2 25 | 65.0% | 8.3% | ||
| Q1 25 | 63.3% | 10.8% | ||
| Q4 24 | 61.6% | 13.9% | ||
| Q3 24 | 61.1% | 13.9% | ||
| Q2 24 | 59.1% | 2.3% | ||
| Q1 24 | 61.2% | -0.6% |
| Q4 25 | -43.0% | -0.9% | ||
| Q3 25 | -37.3% | -33.1% | ||
| Q2 25 | -45.9% | -31.4% | ||
| Q1 25 | -54.6% | -45.5% | ||
| Q4 24 | -62.4% | -26.0% | ||
| Q3 24 | -61.3% | -21.6% | ||
| Q2 24 | -56.8% | -40.3% | ||
| Q1 24 | -59.2% | -42.9% |
| Q4 25 | -45.7% | -15.7% | ||
| Q3 25 | -35.0% | -45.1% | ||
| Q2 25 | -43.0% | -43.4% | ||
| Q1 25 | -46.8% | -55.9% | ||
| Q4 24 | -55.0% | -42.7% | ||
| Q3 24 | -56.3% | -29.8% | ||
| Q2 24 | -57.9% | -49.4% | ||
| Q1 24 | -68.2% | -49.4% |
| Q4 25 | $-1.01 | $-0.04 | ||
| Q3 25 | $-0.74 | $-0.12 | ||
| Q2 25 | $-0.80 | $-0.12 | ||
| Q1 25 | $-0.77 | $-0.14 | ||
| Q4 24 | $-0.90 | $-0.13 | ||
| Q3 24 | $-0.88 | $-0.08 | ||
| Q2 24 | $-0.84 | $-0.14 | ||
| Q1 24 | $-0.94 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $133.9M |
| Total DebtLower is stronger | $1.5B | $671.3M |
| Stockholders' EquityBook value | $-99.3M | $-392.1M |
| Total Assets | $2.0B | $968.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $133.9M | ||
| Q3 25 | $580.0M | $125.3M | ||
| Q2 25 | $629.1M | $107.0M | ||
| Q1 25 | $698.6M | $171.8M | ||
| Q4 24 | $525.5M | $216.4M | ||
| Q3 24 | $585.0M | $115.9M | ||
| Q2 24 | $933.7M | $141.5M | ||
| Q1 24 | $1.0B | $180.9M |
| Q4 25 | $1.5B | $671.3M | ||
| Q3 25 | $1.1B | $766.5M | ||
| Q2 25 | $1.1B | $770.5M | ||
| Q1 25 | $1.1B | $765.8M | ||
| Q4 24 | $1.1B | $761.3M | ||
| Q3 24 | — | $596.9M | ||
| Q2 24 | — | $597.4M | ||
| Q1 24 | — | $603.2M |
| Q4 25 | $-99.3M | $-392.1M | ||
| Q3 25 | $-354.5M | $-374.5M | ||
| Q2 25 | $-305.5M | $-347.8M | ||
| Q1 25 | $-250.8M | $-288.1M | ||
| Q4 24 | $-139.6M | $-202.1M | ||
| Q3 24 | $-60.1M | $-117.7M | ||
| Q2 24 | $-1.6M | $-72.2M | ||
| Q1 24 | $68.3M | $936.0K |
| Q4 25 | $2.0B | $968.8M | ||
| Q3 25 | $1.3B | $973.0M | ||
| Q2 25 | $1.3B | $1.0B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.5B | $1.2B | ||
| Q3 24 | $1.5B | $1.0B | ||
| Q2 24 | $1.6B | $1.1B | ||
| Q1 24 | $1.7B | $1.2B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 644.43× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $-18.4M |
| Free Cash FlowOCF − Capex | $-54.2M | $-58.3M |
| FCF MarginFCF / Revenue | -19.3% | -31.7% |
| Capex IntensityCapex / Revenue | 9.9% | 21.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $-259.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $-18.4M | ||
| Q3 25 | $-35.4M | $-37.1M | ||
| Q2 25 | $-60.3M | $-62.9M | ||
| Q1 25 | $-62.7M | $-47.9M | ||
| Q4 24 | $-64.5M | $37.9M | ||
| Q3 24 | $-51.1M | $-16.9M | ||
| Q2 24 | $-94.0M | $-25.2M | ||
| Q1 24 | $-30.3M | $-73.8M |
| Q4 25 | $-54.2M | $-58.3M | ||
| Q3 25 | $-45.8M | $-60.4M | ||
| Q2 25 | $-65.9M | $-78.6M | ||
| Q1 25 | $-67.1M | $-62.6M | ||
| Q4 24 | $-83.4M | $-70.2M | ||
| Q3 24 | $-55.3M | $-21.9M | ||
| Q2 24 | $-99.1M | $-30.8M | ||
| Q1 24 | $-37.2M | $-77.8M |
| Q4 25 | -19.3% | -31.7% | ||
| Q3 25 | -17.3% | -32.6% | ||
| Q2 25 | -28.4% | -41.5% | ||
| Q1 25 | -33.0% | -35.3% | ||
| Q4 24 | -41.3% | -34.3% | ||
| Q3 24 | -28.9% | -11.3% | ||
| Q2 24 | -55.9% | -15.7% | ||
| Q1 24 | -22.1% | -39.5% |
| Q4 25 | 9.9% | 21.7% | ||
| Q3 25 | 3.9% | 12.5% | ||
| Q2 25 | 2.4% | 8.3% | ||
| Q1 25 | 2.2% | 8.3% | ||
| Q4 24 | 9.4% | 52.8% | ||
| Q3 24 | 2.2% | 2.6% | ||
| Q2 24 | 2.9% | 2.9% | ||
| Q1 24 | 4.1% | 2.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
UP
Segment breakdown not available.
